Maze Therapeutics (MAZE) Stock Price, News & Analysis

Company Overview

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages.

Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.

Key Stats

• Today's Range: $27.34 to $29.45
• 50-Day Range: $13.14 to $28.76
• 52-Week Range: $6.71 to $29.66
• Volume: 261,742 shs
• Average Volume: 298,534 shs
• Market Capitalization: $1.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.83
• Consensus Rating: Buy

Maze Therapeutics Stock Analysis - MarketRank™

Maze Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 308th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Buy

Consensus Rating

Maze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Maze Therapeutics has a consensus price target of $33.83, representing about 23.3% upside from its current price of $27.43.

Amount of Analyst Coverage

Maze Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.33% of the float of Maze Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Maze Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Maze Therapeutics has recently decreased by 5.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maze Therapeutics does not currently pay a dividend.

Dividend Growth

Maze Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.33% of the float of Maze Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Maze Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Maze Therapeutics has recently decreased by 5.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.41

News Sentiment

Maze Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for MAZE on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

MarketBeat Follows

20 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,900% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $464,043.00 in company stock.

MAZE Stock Analysis - Frequently Asked Questions

How have MAZE shares performed this year?

Maze Therapeutics' stock was trading at $13.38 at the beginning of the year. Since then, MAZE stock has increased by 105.0% and is now trading at $27.43.

How were Maze Therapeutics' earnings last quarter?

Maze Therapeutics, Inc. (NASDAQ:MAZE) issued its earnings results on Tuesday, August, 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

When did Maze Therapeutics IPO?

Maze Therapeutics (MAZE) raised $140 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 8,750,000 shares at $16.00 per share.

How do I buy shares of Maze Therapeutics?

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MAZE
• Previous Symbol: NASDAQ:MAZE
• CIK: 1842295
• Web: N/A
• Phone: (650) 850-5070
• Fax: N/A
• Employees: 121
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Maze Therapeutics: $33.83
• High Price Target: $50.00
• Low Price Target: $17.00
• Potential Upside/Downside: +20.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.63
• Quick Ratio: 13.63

Sales & Book Value

• Annual Sales: $167.50 million
• Price / Sales: 7.33
• Cash Flow: $0.15 per share
• Price / Cash Flow: 186.78
• Book Value: ($7.11) per share
• Price / Book: -3.94

Miscellaneous

• Outstanding Shares: 43,850,000
• Free Float: N/A
• Market Cap: $1.23 billion
• Optionable: N/A
• Beta: N/A